$ 229.13
Key Takeaways
Risk factor
Negligible price volatility
Profitability factor
Overvalued vs peers
About
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, 'expensive' on EV/EBI
Target Price
The average target price of ABBV is 220 and suggests 4% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decre
